Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tilpisertib Fosmecarbil in Moderately to Severely Active Ulcerative Colitis
NCT06029972Phase 2Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Dec 2023
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 2, randomised, double-blind trial of tilpisertib fosmecarbil in ulcerative colitis (UC) (4 arms), sponsored by Gilead Sciences. Primary endpoint: Proportion of Participants Achieving Clinical Response Per Modified Mayo Clinic Score at 12 weeks. Started Dec 2023; status: active, not recruiting.
02
Drugs
tilpisertib fosmecarbil
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06029972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06029972.